The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Rhythm Pharmaceuticals Inc shares valued at $1,767,006 were sold by Shulman Joseph on Sep 02 ’25. At $105.30 per share, Shulman Joseph sold 16,781 shares. The insider’s holdings dropped to 8,509 shares worth approximately $0.82 million following the completion of this transaction.
Also, JOSEPH SHULMAN purchased 16,781 shares, netting a total of over 1,730,960 in proceeds.
Before that, Shulman Joseph had sold 4,188 shares from its account. In a trade valued at $419,091, the Chief Technical Officer traded Rhythm Pharmaceuticals Inc shares for $100.07 each. Upon closing the transaction, the insider’s holdings decreased to 4,188 shares, worth approximately $0.82 million.
As published in their initiating research note from Goldman on July 10, 2025, Rhythm Pharmaceuticals Inc [RYTM] has been a Buy and the price target has been revised to $97. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in early July. As of April 07, 2025, BofA Securities has increased its “Neutral” rating to a “Buy” for RYTM.
Analyzing RYTM Stock Performance
On last trading session, Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] rose 0.61% to $96.1. The stock’s lowest price that day was $96.02, but it reached a high of $97.895 in the same session. During the last five days, there has been a drop of approximately -4.16%. Over the course of the year, Rhythm Pharmaceuticals Inc shares have jumped approximately 93.67%.
Is Rhythm Pharmaceuticals Inc subject to short interest?
Stocks of Rhythm Pharmaceuticals Inc saw a sharp rise in short interest on 2025-08-29 jumping by 0.46 million shares to 4.97 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 4.51 million shares. A jump of 9.16% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.82 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.82.
Which companies own the most shares of Rhythm Pharmaceuticals Inc (RYTM)?
In terms of Rhythm Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 109 in the next 12 months, up nearly 14.12% from the previous closing price of $95.51. Analysts anticipate Rhythm Pharmaceuticals Inc stock to reach 110 by 2025, with the lowest price target being 97. In spite of this, 5 analysts ranked Rhythm Pharmaceuticals Inc stock as Buy at the end of 2025. On January 02, 2025, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $80.
